Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells

Ferroptosis is a recently recognized form of regulated cell death that is characterized by lipid peroxidation. However, the molecular mechanisms regulating ferroptosis are largely unknown. In this study, we report that the RNA-binding protein ELAVL1/HuR plays a crucial role in regulating ferroptosis...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Autophagy 2018-12, Vol.14 (12), p.2083-2103
Hauptverfasser: Zhang, Zili, Yao, Zhen, Wang, Ling, Ding, Hai, Shao, Jiangjuan, Chen, Anping, Zhang, Feng, Zheng, Shizhong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2103
container_issue 12
container_start_page 2083
container_title Autophagy
container_volume 14
creator Zhang, Zili
Yao, Zhen
Wang, Ling
Ding, Hai
Shao, Jiangjuan
Chen, Anping
Zhang, Feng
Zheng, Shizhong
description Ferroptosis is a recently recognized form of regulated cell death that is characterized by lipid peroxidation. However, the molecular mechanisms regulating ferroptosis are largely unknown. In this study, we report that the RNA-binding protein ELAVL1/HuR plays a crucial role in regulating ferroptosis in liver fibrosis. Upon exposure to ferroptosis-inducing compounds, ELAVL1 protein expression was remarkably increased through the inhibition of the ubiquitin-proteasome pathway. ELAVL1 siRNA led to ferroptosis resistance, whereas ELAVL1 plasmid contributed to classical ferroptotic events. Interestingly, upregulated ELAVL1 expression also appeared to increase autophagosome generation and macroautophagic/autophagic flux, which was the underlying mechanism for ELAVL1-enhanced ferroptosis. Autophagy depletion completely impaired ELAVL1-mediated ferroptotic events, whereas autophagy induction showed a synergistic effect with ELAVL1. Importantly, ELAVL1 promoted autophagy activation via binding to the AU-rich elements within the F3 of the 3ʹ-untranslated region of BECN1/Beclin1 mRNA. The internal deletion of the F3 region abrogated the ELAVL1-mediated BECN1 mRNA stability, and, in turn, prevented ELAVL1-enhanced ferroptosis. In mice, treatment with sorafenib alleviated murine liver fibrosis by inducing hepatic stellate cell (HSC) ferroptosis. HSC-specific knockdown of ELAVL1 impaired sorafenib-induced HSC ferroptosis in murine liver fibrosis. Noteworthy, we retrospectively analyzed the effect of sorafenib on HSC ferroptosis in advanced fibrotic patients with hepatocellular carcinoma receiving sorafenib monotherapy. Attractively, ELAVL1 upregulation, ferritinophagy activation, and ferroptosis induction occurred in primary human HSCs from the collected human liver tissue. Overall, these results reveal novel molecular mechanisms and signaling pathways of ferroptosis, and also identify ELAVL1-autophagy-dependent ferroptosis as a potential target for the treatment of liver fibrosis. Abbreviations: ACTA2/alpha-SMA: actin, alpha 2, smooth muscle, aorta; ACTB/beta-actin: actin beta; ARE: AU-rich element; ATG: autophagy related; BDL: bile duct ligation; BECN1: beclin 1; BSO: buthionine sulfoximine; COL1A1: collagen type I alpha 1 chain; ELAVL1/HuR: ELAV like RNA binding protein 1; FDA: fluorescein diacetate; FTH1: ferritin heavy chain 1; GOT1/AST: glutamic-oxaloacetic transaminase 1; GPT/ALT: glutamic-pyruvic transaminase; GPX4: glutathione peroxidase 4; GSH: glutathione; HC
doi_str_mv 10.1080/15548627.2018.1503146
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_30081711</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2084923754</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-63968e5b9336549738d2ea81abf98f914f8ff3fd853413864953e3d0263b67d83</originalsourceid><addsrcrecordid>eNp9kc1uGyEUhVGVqknTPkIrltmMA8PPwCaKFaVJJauVorZbxMyATTWGCTCJvOybB8eOlWy6uoj7nXNAB4AvGM0wEugcM0YFr5tZjbCYYYYIpvwdONneV4ITdnQ4180x-JjSX4QIF7L-AI4JQgI3GJ-Af_MuuwedXfAwWGhNjC47H8aVXm6gSzCa-8lF00MbIswrA-9-zKvW-d75JRxjyMZ5eL2Y_1ng89vpDuZQJMtp0Nk8u4Uxh1R8CrUyYwnqYMpmeN53ZaZP4L3VQzKf9_MU_P52_evqtlr8vPl-NV9UHSM0V5xILgxrJSGcUdkQ0ddGC6xbK4WVmFphLbG9KDQmglPJiCE9qjlpedMLcgoudr7j1K5N3xmfox7UGN1ax40K2qm3G-9WahkeFJeCNpwVg7O9QQz3k0lZrV3afkF7E6akaiSorEnDaEHZDu1iSCkae4jBSG3rUy_1qW19al9f0X19_caD6qWvAlzuAOdLH2v9GOLQq6w3Q4g2at-5pMj_M54A6NWrgw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2084923754</pqid></control><display><type>article</type><title>Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells</title><source>Open Access: PubMed Central</source><source>MEDLINE</source><source>EZB Electronic Journals Library</source><creator>Zhang, Zili ; Yao, Zhen ; Wang, Ling ; Ding, Hai ; Shao, Jiangjuan ; Chen, Anping ; Zhang, Feng ; Zheng, Shizhong</creator><creatorcontrib>Zhang, Zili ; Yao, Zhen ; Wang, Ling ; Ding, Hai ; Shao, Jiangjuan ; Chen, Anping ; Zhang, Feng ; Zheng, Shizhong</creatorcontrib><description>Ferroptosis is a recently recognized form of regulated cell death that is characterized by lipid peroxidation. However, the molecular mechanisms regulating ferroptosis are largely unknown. In this study, we report that the RNA-binding protein ELAVL1/HuR plays a crucial role in regulating ferroptosis in liver fibrosis. Upon exposure to ferroptosis-inducing compounds, ELAVL1 protein expression was remarkably increased through the inhibition of the ubiquitin-proteasome pathway. ELAVL1 siRNA led to ferroptosis resistance, whereas ELAVL1 plasmid contributed to classical ferroptotic events. Interestingly, upregulated ELAVL1 expression also appeared to increase autophagosome generation and macroautophagic/autophagic flux, which was the underlying mechanism for ELAVL1-enhanced ferroptosis. Autophagy depletion completely impaired ELAVL1-mediated ferroptotic events, whereas autophagy induction showed a synergistic effect with ELAVL1. Importantly, ELAVL1 promoted autophagy activation via binding to the AU-rich elements within the F3 of the 3ʹ-untranslated region of BECN1/Beclin1 mRNA. The internal deletion of the F3 region abrogated the ELAVL1-mediated BECN1 mRNA stability, and, in turn, prevented ELAVL1-enhanced ferroptosis. In mice, treatment with sorafenib alleviated murine liver fibrosis by inducing hepatic stellate cell (HSC) ferroptosis. HSC-specific knockdown of ELAVL1 impaired sorafenib-induced HSC ferroptosis in murine liver fibrosis. Noteworthy, we retrospectively analyzed the effect of sorafenib on HSC ferroptosis in advanced fibrotic patients with hepatocellular carcinoma receiving sorafenib monotherapy. Attractively, ELAVL1 upregulation, ferritinophagy activation, and ferroptosis induction occurred in primary human HSCs from the collected human liver tissue. Overall, these results reveal novel molecular mechanisms and signaling pathways of ferroptosis, and also identify ELAVL1-autophagy-dependent ferroptosis as a potential target for the treatment of liver fibrosis. Abbreviations: ACTA2/alpha-SMA: actin, alpha 2, smooth muscle, aorta; ACTB/beta-actin: actin beta; ARE: AU-rich element; ATG: autophagy related; BDL: bile duct ligation; BECN1: beclin 1; BSO: buthionine sulfoximine; COL1A1: collagen type I alpha 1 chain; ELAVL1/HuR: ELAV like RNA binding protein 1; FDA: fluorescein diacetate; FTH1: ferritin heavy chain 1; GOT1/AST: glutamic-oxaloacetic transaminase 1; GPT/ALT: glutamic-pyruvic transaminase; GPX4: glutathione peroxidase 4; GSH: glutathione; HCC: hepatocellular carcinoma; HSC: hepatic stellate cell; LCM: laser capture microdissection; MAP1LC3B: microtubule associated protein 1 light chain 3 beta; MDA: malondialdehydep; NCOA4: nuclear receptor coactivator 4; PTGS2: prostaglandin-endoperoxide synthase 2; ROS: reactive oxygen species; SQSTM1/p62: sequestosome 1; TBIL: total bilirubin; TEM: transmission electron microscopy; TGFB1: trasforming growth factor beta 1; UTR: untranslated region; VA-Lip-ELAVL1-siRNA: vitamin A-coupled liposomes carrying ELAVL1-siRNA.</description><identifier>ISSN: 1554-8627</identifier><identifier>EISSN: 1554-8635</identifier><identifier>DOI: 10.1080/15548627.2018.1503146</identifier><identifier>PMID: 30081711</identifier><language>eng</language><publisher>United States: Taylor &amp; Francis</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Animals ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Autophagy ; Autophagy - drug effects ; Autophagy - genetics ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - genetics ; Carcinoma, Hepatocellular - pathology ; Cell Death - drug effects ; Cell Death - physiology ; Cells, Cultured ; Chemical and Drug Induced Liver Injury - genetics ; Chemical and Drug Induced Liver Injury - metabolism ; Chemical and Drug Induced Liver Injury - pathology ; ELAV-Like Protein 1 - genetics ; ELAV-Like Protein 1 - physiology ; ELAVL1 ; Female ; ferritinophagy ; ferroptosis ; hepatic stellate cell ; Hepatic Stellate Cells - drug effects ; Hepatic Stellate Cells - metabolism ; Hepatic Stellate Cells - pathology ; Humans ; Iron - pharmacology ; Lipid Peroxidation - drug effects ; Lipid Peroxidation - physiology ; Liver Cirrhosis - chemically induced ; Liver Cirrhosis - genetics ; Liver Cirrhosis - metabolism ; Liver Cirrhosis - pathology ; liver fibrosis ; Liver Neoplasms - drug therapy ; Liver Neoplasms - genetics ; Liver Neoplasms - pathology ; Male ; Mice ; Mice, Inbred C57BL ; Middle Aged ; Research Paper - Basic Science ; Retrospective Studies ; Sorafenib - administration &amp; dosage ; Sorafenib - adverse effects ; Sorafenib - pharmacology ; therapeutic target</subject><ispartof>Autophagy, 2018-12, Vol.14 (12), p.2083-2103</ispartof><rights>2018 Informa UK Limited, trading as Taylor &amp; Francis Group 2018</rights><rights>2018 Informa UK Limited, trading as Taylor &amp; Francis Group 2018 Informa UK Limited, trading as Taylor &amp; Francis Group</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-63968e5b9336549738d2ea81abf98f914f8ff3fd853413864953e3d0263b67d83</citedby><cites>FETCH-LOGICAL-c534t-63968e5b9336549738d2ea81abf98f914f8ff3fd853413864953e3d0263b67d83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984765/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984765/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30081711$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Zili</creatorcontrib><creatorcontrib>Yao, Zhen</creatorcontrib><creatorcontrib>Wang, Ling</creatorcontrib><creatorcontrib>Ding, Hai</creatorcontrib><creatorcontrib>Shao, Jiangjuan</creatorcontrib><creatorcontrib>Chen, Anping</creatorcontrib><creatorcontrib>Zhang, Feng</creatorcontrib><creatorcontrib>Zheng, Shizhong</creatorcontrib><title>Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells</title><title>Autophagy</title><addtitle>Autophagy</addtitle><description>Ferroptosis is a recently recognized form of regulated cell death that is characterized by lipid peroxidation. However, the molecular mechanisms regulating ferroptosis are largely unknown. In this study, we report that the RNA-binding protein ELAVL1/HuR plays a crucial role in regulating ferroptosis in liver fibrosis. Upon exposure to ferroptosis-inducing compounds, ELAVL1 protein expression was remarkably increased through the inhibition of the ubiquitin-proteasome pathway. ELAVL1 siRNA led to ferroptosis resistance, whereas ELAVL1 plasmid contributed to classical ferroptotic events. Interestingly, upregulated ELAVL1 expression also appeared to increase autophagosome generation and macroautophagic/autophagic flux, which was the underlying mechanism for ELAVL1-enhanced ferroptosis. Autophagy depletion completely impaired ELAVL1-mediated ferroptotic events, whereas autophagy induction showed a synergistic effect with ELAVL1. Importantly, ELAVL1 promoted autophagy activation via binding to the AU-rich elements within the F3 of the 3ʹ-untranslated region of BECN1/Beclin1 mRNA. The internal deletion of the F3 region abrogated the ELAVL1-mediated BECN1 mRNA stability, and, in turn, prevented ELAVL1-enhanced ferroptosis. In mice, treatment with sorafenib alleviated murine liver fibrosis by inducing hepatic stellate cell (HSC) ferroptosis. HSC-specific knockdown of ELAVL1 impaired sorafenib-induced HSC ferroptosis in murine liver fibrosis. Noteworthy, we retrospectively analyzed the effect of sorafenib on HSC ferroptosis in advanced fibrotic patients with hepatocellular carcinoma receiving sorafenib monotherapy. Attractively, ELAVL1 upregulation, ferritinophagy activation, and ferroptosis induction occurred in primary human HSCs from the collected human liver tissue. Overall, these results reveal novel molecular mechanisms and signaling pathways of ferroptosis, and also identify ELAVL1-autophagy-dependent ferroptosis as a potential target for the treatment of liver fibrosis. Abbreviations: ACTA2/alpha-SMA: actin, alpha 2, smooth muscle, aorta; ACTB/beta-actin: actin beta; ARE: AU-rich element; ATG: autophagy related; BDL: bile duct ligation; BECN1: beclin 1; BSO: buthionine sulfoximine; COL1A1: collagen type I alpha 1 chain; ELAVL1/HuR: ELAV like RNA binding protein 1; FDA: fluorescein diacetate; FTH1: ferritin heavy chain 1; GOT1/AST: glutamic-oxaloacetic transaminase 1; GPT/ALT: glutamic-pyruvic transaminase; GPX4: glutathione peroxidase 4; GSH: glutathione; HCC: hepatocellular carcinoma; HSC: hepatic stellate cell; LCM: laser capture microdissection; MAP1LC3B: microtubule associated protein 1 light chain 3 beta; MDA: malondialdehydep; NCOA4: nuclear receptor coactivator 4; PTGS2: prostaglandin-endoperoxide synthase 2; ROS: reactive oxygen species; SQSTM1/p62: sequestosome 1; TBIL: total bilirubin; TEM: transmission electron microscopy; TGFB1: trasforming growth factor beta 1; UTR: untranslated region; VA-Lip-ELAVL1-siRNA: vitamin A-coupled liposomes carrying ELAVL1-siRNA.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Animals</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Autophagy</subject><subject>Autophagy - drug effects</subject><subject>Autophagy - genetics</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - genetics</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Cell Death - drug effects</subject><subject>Cell Death - physiology</subject><subject>Cells, Cultured</subject><subject>Chemical and Drug Induced Liver Injury - genetics</subject><subject>Chemical and Drug Induced Liver Injury - metabolism</subject><subject>Chemical and Drug Induced Liver Injury - pathology</subject><subject>ELAV-Like Protein 1 - genetics</subject><subject>ELAV-Like Protein 1 - physiology</subject><subject>ELAVL1</subject><subject>Female</subject><subject>ferritinophagy</subject><subject>ferroptosis</subject><subject>hepatic stellate cell</subject><subject>Hepatic Stellate Cells - drug effects</subject><subject>Hepatic Stellate Cells - metabolism</subject><subject>Hepatic Stellate Cells - pathology</subject><subject>Humans</subject><subject>Iron - pharmacology</subject><subject>Lipid Peroxidation - drug effects</subject><subject>Lipid Peroxidation - physiology</subject><subject>Liver Cirrhosis - chemically induced</subject><subject>Liver Cirrhosis - genetics</subject><subject>Liver Cirrhosis - metabolism</subject><subject>Liver Cirrhosis - pathology</subject><subject>liver fibrosis</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - genetics</subject><subject>Liver Neoplasms - pathology</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Middle Aged</subject><subject>Research Paper - Basic Science</subject><subject>Retrospective Studies</subject><subject>Sorafenib - administration &amp; dosage</subject><subject>Sorafenib - adverse effects</subject><subject>Sorafenib - pharmacology</subject><subject>therapeutic target</subject><issn>1554-8627</issn><issn>1554-8635</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1uGyEUhVGVqknTPkIrltmMA8PPwCaKFaVJJauVorZbxMyATTWGCTCJvOybB8eOlWy6uoj7nXNAB4AvGM0wEugcM0YFr5tZjbCYYYYIpvwdONneV4ITdnQ4180x-JjSX4QIF7L-AI4JQgI3GJ-Af_MuuwedXfAwWGhNjC47H8aVXm6gSzCa-8lF00MbIswrA-9-zKvW-d75JRxjyMZ5eL2Y_1ng89vpDuZQJMtp0Nk8u4Uxh1R8CrUyYwnqYMpmeN53ZaZP4L3VQzKf9_MU_P52_evqtlr8vPl-NV9UHSM0V5xILgxrJSGcUdkQ0ddGC6xbK4WVmFphLbG9KDQmglPJiCE9qjlpedMLcgoudr7j1K5N3xmfox7UGN1ax40K2qm3G-9WahkeFJeCNpwVg7O9QQz3k0lZrV3afkF7E6akaiSorEnDaEHZDu1iSCkae4jBSG3rUy_1qW19al9f0X19_caD6qWvAlzuAOdLH2v9GOLQq6w3Q4g2at-5pMj_M54A6NWrgw</recordid><startdate>20181202</startdate><enddate>20181202</enddate><creator>Zhang, Zili</creator><creator>Yao, Zhen</creator><creator>Wang, Ling</creator><creator>Ding, Hai</creator><creator>Shao, Jiangjuan</creator><creator>Chen, Anping</creator><creator>Zhang, Feng</creator><creator>Zheng, Shizhong</creator><general>Taylor &amp; Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20181202</creationdate><title>Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells</title><author>Zhang, Zili ; Yao, Zhen ; Wang, Ling ; Ding, Hai ; Shao, Jiangjuan ; Chen, Anping ; Zhang, Feng ; Zheng, Shizhong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-63968e5b9336549738d2ea81abf98f914f8ff3fd853413864953e3d0263b67d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Animals</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Autophagy</topic><topic>Autophagy - drug effects</topic><topic>Autophagy - genetics</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - genetics</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Cell Death - drug effects</topic><topic>Cell Death - physiology</topic><topic>Cells, Cultured</topic><topic>Chemical and Drug Induced Liver Injury - genetics</topic><topic>Chemical and Drug Induced Liver Injury - metabolism</topic><topic>Chemical and Drug Induced Liver Injury - pathology</topic><topic>ELAV-Like Protein 1 - genetics</topic><topic>ELAV-Like Protein 1 - physiology</topic><topic>ELAVL1</topic><topic>Female</topic><topic>ferritinophagy</topic><topic>ferroptosis</topic><topic>hepatic stellate cell</topic><topic>Hepatic Stellate Cells - drug effects</topic><topic>Hepatic Stellate Cells - metabolism</topic><topic>Hepatic Stellate Cells - pathology</topic><topic>Humans</topic><topic>Iron - pharmacology</topic><topic>Lipid Peroxidation - drug effects</topic><topic>Lipid Peroxidation - physiology</topic><topic>Liver Cirrhosis - chemically induced</topic><topic>Liver Cirrhosis - genetics</topic><topic>Liver Cirrhosis - metabolism</topic><topic>Liver Cirrhosis - pathology</topic><topic>liver fibrosis</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - genetics</topic><topic>Liver Neoplasms - pathology</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Middle Aged</topic><topic>Research Paper - Basic Science</topic><topic>Retrospective Studies</topic><topic>Sorafenib - administration &amp; dosage</topic><topic>Sorafenib - adverse effects</topic><topic>Sorafenib - pharmacology</topic><topic>therapeutic target</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Zili</creatorcontrib><creatorcontrib>Yao, Zhen</creatorcontrib><creatorcontrib>Wang, Ling</creatorcontrib><creatorcontrib>Ding, Hai</creatorcontrib><creatorcontrib>Shao, Jiangjuan</creatorcontrib><creatorcontrib>Chen, Anping</creatorcontrib><creatorcontrib>Zhang, Feng</creatorcontrib><creatorcontrib>Zheng, Shizhong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Autophagy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Zili</au><au>Yao, Zhen</au><au>Wang, Ling</au><au>Ding, Hai</au><au>Shao, Jiangjuan</au><au>Chen, Anping</au><au>Zhang, Feng</au><au>Zheng, Shizhong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells</atitle><jtitle>Autophagy</jtitle><addtitle>Autophagy</addtitle><date>2018-12-02</date><risdate>2018</risdate><volume>14</volume><issue>12</issue><spage>2083</spage><epage>2103</epage><pages>2083-2103</pages><issn>1554-8627</issn><eissn>1554-8635</eissn><abstract>Ferroptosis is a recently recognized form of regulated cell death that is characterized by lipid peroxidation. However, the molecular mechanisms regulating ferroptosis are largely unknown. In this study, we report that the RNA-binding protein ELAVL1/HuR plays a crucial role in regulating ferroptosis in liver fibrosis. Upon exposure to ferroptosis-inducing compounds, ELAVL1 protein expression was remarkably increased through the inhibition of the ubiquitin-proteasome pathway. ELAVL1 siRNA led to ferroptosis resistance, whereas ELAVL1 plasmid contributed to classical ferroptotic events. Interestingly, upregulated ELAVL1 expression also appeared to increase autophagosome generation and macroautophagic/autophagic flux, which was the underlying mechanism for ELAVL1-enhanced ferroptosis. Autophagy depletion completely impaired ELAVL1-mediated ferroptotic events, whereas autophagy induction showed a synergistic effect with ELAVL1. Importantly, ELAVL1 promoted autophagy activation via binding to the AU-rich elements within the F3 of the 3ʹ-untranslated region of BECN1/Beclin1 mRNA. The internal deletion of the F3 region abrogated the ELAVL1-mediated BECN1 mRNA stability, and, in turn, prevented ELAVL1-enhanced ferroptosis. In mice, treatment with sorafenib alleviated murine liver fibrosis by inducing hepatic stellate cell (HSC) ferroptosis. HSC-specific knockdown of ELAVL1 impaired sorafenib-induced HSC ferroptosis in murine liver fibrosis. Noteworthy, we retrospectively analyzed the effect of sorafenib on HSC ferroptosis in advanced fibrotic patients with hepatocellular carcinoma receiving sorafenib monotherapy. Attractively, ELAVL1 upregulation, ferritinophagy activation, and ferroptosis induction occurred in primary human HSCs from the collected human liver tissue. Overall, these results reveal novel molecular mechanisms and signaling pathways of ferroptosis, and also identify ELAVL1-autophagy-dependent ferroptosis as a potential target for the treatment of liver fibrosis. Abbreviations: ACTA2/alpha-SMA: actin, alpha 2, smooth muscle, aorta; ACTB/beta-actin: actin beta; ARE: AU-rich element; ATG: autophagy related; BDL: bile duct ligation; BECN1: beclin 1; BSO: buthionine sulfoximine; COL1A1: collagen type I alpha 1 chain; ELAVL1/HuR: ELAV like RNA binding protein 1; FDA: fluorescein diacetate; FTH1: ferritin heavy chain 1; GOT1/AST: glutamic-oxaloacetic transaminase 1; GPT/ALT: glutamic-pyruvic transaminase; GPX4: glutathione peroxidase 4; GSH: glutathione; HCC: hepatocellular carcinoma; HSC: hepatic stellate cell; LCM: laser capture microdissection; MAP1LC3B: microtubule associated protein 1 light chain 3 beta; MDA: malondialdehydep; NCOA4: nuclear receptor coactivator 4; PTGS2: prostaglandin-endoperoxide synthase 2; ROS: reactive oxygen species; SQSTM1/p62: sequestosome 1; TBIL: total bilirubin; TEM: transmission electron microscopy; TGFB1: trasforming growth factor beta 1; UTR: untranslated region; VA-Lip-ELAVL1-siRNA: vitamin A-coupled liposomes carrying ELAVL1-siRNA.</abstract><cop>United States</cop><pub>Taylor &amp; Francis</pub><pmid>30081711</pmid><doi>10.1080/15548627.2018.1503146</doi><tpages>21</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1554-8627
ispartof Autophagy, 2018-12, Vol.14 (12), p.2083-2103
issn 1554-8627
1554-8635
language eng
recordid cdi_pubmed_primary_30081711
source Open Access: PubMed Central; MEDLINE; EZB Electronic Journals Library
subjects Adult
Aged
Aged, 80 and over
Animals
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Autophagy
Autophagy - drug effects
Autophagy - genetics
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - genetics
Carcinoma, Hepatocellular - pathology
Cell Death - drug effects
Cell Death - physiology
Cells, Cultured
Chemical and Drug Induced Liver Injury - genetics
Chemical and Drug Induced Liver Injury - metabolism
Chemical and Drug Induced Liver Injury - pathology
ELAV-Like Protein 1 - genetics
ELAV-Like Protein 1 - physiology
ELAVL1
Female
ferritinophagy
ferroptosis
hepatic stellate cell
Hepatic Stellate Cells - drug effects
Hepatic Stellate Cells - metabolism
Hepatic Stellate Cells - pathology
Humans
Iron - pharmacology
Lipid Peroxidation - drug effects
Lipid Peroxidation - physiology
Liver Cirrhosis - chemically induced
Liver Cirrhosis - genetics
Liver Cirrhosis - metabolism
Liver Cirrhosis - pathology
liver fibrosis
Liver Neoplasms - drug therapy
Liver Neoplasms - genetics
Liver Neoplasms - pathology
Male
Mice
Mice, Inbred C57BL
Middle Aged
Research Paper - Basic Science
Retrospective Studies
Sorafenib - administration & dosage
Sorafenib - adverse effects
Sorafenib - pharmacology
therapeutic target
title Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T11%3A04%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Activation%20of%20ferritinophagy%20is%20required%20for%20the%20RNA-binding%20protein%20ELAVL1/HuR%20to%20regulate%20ferroptosis%20in%20hepatic%20stellate%20cells&rft.jtitle=Autophagy&rft.au=Zhang,%20Zili&rft.date=2018-12-02&rft.volume=14&rft.issue=12&rft.spage=2083&rft.epage=2103&rft.pages=2083-2103&rft.issn=1554-8627&rft.eissn=1554-8635&rft_id=info:doi/10.1080/15548627.2018.1503146&rft_dat=%3Cproquest_pubme%3E2084923754%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2084923754&rft_id=info:pmid/30081711&rfr_iscdi=true